Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis
about
Optimal management of dactylitis in patients with psoriatic arthritisSmartphone-based multispectral imaging: system development and potential for mobile skin diagnosis.Diagnosis and management of psoriasis.Diagnostic et prise en charge du psoriasisA comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritisSmall Molecules in the Treatment of Psoriasis.Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm MeetingRadical-mediated dehydrative preparation of cyclic imides using (NH4)2S2O8-DMSO: application to the synthesis of vernakalant.Apremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis.Estrogen and progesterone decrease let-7f microRNA expression and increase IL-23/IL-23 receptor signaling and IL-17A production in patients with severe asthma.East Indian Sandalwood Oil (EISO) Alleviates Inflammatory and Proliferative Pathologies of Psoriasis.Apremilast: first global approval.Emerging oral drugs for psoriasis.Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.Novel approaches to biological therapy for psoriatic arthritis.Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients.Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region.Improvements in diagnostic tools for early detection of psoriatic arthritis.Secukinumab: A Review in Psoriatic Arthritis.Secukinumab: a promising therapeutic option in spondyloarthritis.Performance of screening tools for psoriatic arthritis: a cross-sectional study in primary care.Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.A novel biological target for the treatment of psoriatic arthritis.Effectiveness and safety of infliximab for 11 years in a patient with erythrodermic psoriasis and psoriatic arthritis.Abrupt generalized pustules in patients with rheumatoid arthritis and interstitial lung disease.The Immunogenetics of Psoriasis and Implications for Drug Repositioning.Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology-Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients.Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.Association of Cytotoxic T Lymphocyte Antigen-4 Gene Polymorphisms with Psoriasis Vulgaris: A Case-Control Study in Turkish Population.Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK.Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
P2860
Q28072557-55763AF7-AF6C-49D1-BBD9-DF413CAC8F8FQ33452053-4318DD14-2A19-4674-979B-05940AB844D8Q33558495-681CEEB8-8108-4363-84B4-6C174DAC1E63Q33558550-F75DA4E8-B4E3-482D-B9A2-1956FF0990C7Q35326449-F326C6E2-4E5F-4BA2-A807-C75013E02197Q35740706-C3B625E8-2DCA-4047-9D45-D086EFF3111EQ35822379-5A44F1A2-7249-43C6-821A-7312DC4F7E17Q35859643-37955033-BF7A-4780-A244-22FCE7D5F933Q35896444-E513D970-2A59-4EA0-A704-02D28F6C4451Q36144847-FF236F77-4ED6-4D0C-8ACC-9D9CF3FF70E8Q37703061-3D2D8C22-D8AC-4860-BC6E-2E551498D8E7Q38209439-DA8AAE43-7ABF-4E0A-8984-C77BDEA7CB2CQ38341175-442BEAAB-17C6-4C0C-995B-62F400D0EC41Q38630548-F32F768C-B9A8-4B97-8EFD-E402E163FE92Q38634276-52AC290E-F9B4-48D2-9842-BA697945F83FQ38672570-13AA94DE-E1D1-47D2-B0BA-702B3DA3FB85Q38838470-C505B0FF-091A-46DA-B845-CC7ED5789314Q38861057-A6D84E97-E63C-4616-9002-34ABB7E6A34DQ38864743-5500CAC4-8662-4006-95FD-0121DA993282Q38903129-844DB641-BC57-41ED-AA0C-9DFF7D60C171Q40408596-998F10CC-FE90-465C-83FA-D24083DD5A9EQ40740817-85895825-7079-415E-806B-2D234B6AA89DQ44268181-D32ED94D-CB5C-433F-A1A5-5EFC164CBD73Q44278293-2D8CF1C5-6F8C-4122-A8B9-63EE7F5E3909Q48248832-D3053DA5-7DF1-4653-A0B6-C12B684BE202Q48324692-5C29577F-4913-44B5-BF88-114EDD4898EDQ49560724-D78FABA4-6068-4DB3-A1D1-F9DD1ABF3B9FQ49850238-EB3001D0-1E85-4E5B-A6BA-EE364DAC9177Q55092088-90188A01-71F5-4EBF-8FC1-AB827D8C9330Q55452701-39924771-9F77-4AB4-9593-EC7A00FE90E8Q57169747-DC6B8AA5-85D3-403D-8A53-377D50CF0DEA
P2860
Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Managing patients with psoriat ...... tis in patients with psoriasis
@ast
Managing patients with psoriat ...... tis in patients with psoriasis
@en
Managing patients with psoriat ...... tis in patients with psoriasis
@nl
type
label
Managing patients with psoriat ...... tis in patients with psoriasis
@ast
Managing patients with psoriat ...... tis in patients with psoriasis
@en
Managing patients with psoriat ...... tis in patients with psoriasis
@nl
prefLabel
Managing patients with psoriat ...... tis in patients with psoriasis
@ast
Managing patients with psoriat ...... tis in patients with psoriasis
@en
Managing patients with psoriat ...... tis in patients with psoriasis
@nl
P2860
P921
P3181
P1433
P1476
Managing patients with psoriat ...... tis in patients with psoriasis
@en
P2093
April W. Armstrong
Philip J. Mease
P2860
P2888
P304
P3181
P356
10.1007/S40265-014-0191-Y
P407
P577
2014-03-01T00:00:00Z
P5875
P6179
1052835422